Last updated on November 2018

Golimumab (MK-8259 / SCH900259) Treatment Withdrawal in Participants With Non-radiographic Axial Spondyloarthritis (MK-8259-038)


Brief description of study

The purpose of this study is to evaluate the effect of treatment withdrawal vs continued treatment with golimumab (GLM) administered by subcutaneous (SC) injection on the incidence of a "flare" in non-radiographic axial spondyloarthritis over up to 12 months. The primary hypothesis is that continued treatment with golimumab is superior to treatment withdrawal, based on the percentage of subjects without a "flare" during up to 12 months of blinded therapy.

Clinical Study Identifier: NCT03253796

Contact Investigators or Research Sites near you

Start Over

Study Coordinator

Lubelskie Centrum Diagnostyczne ( Site 0053)
Swidnik, Poland
  Connect »

Study Coordinator

NZOZ Reumed ( Site 0051)
Lublin, Poland
5.7miles
  Connect »

Recruitment Status: Open


Brief Description Eligibility Contact Research Team


Receive Emails About New Clinical Trials!

Sign up for our FREE service to receive email notifications when clinical trials are posted in the medical category of interest to you.